Zobrazeno 1 - 6 of 6 pro vyhledávání: '"Cindy Duval Fraser"'
3
Abstract P3-10-06: Real-world efficacy and safety outcomes of nab-paclitaxel (nab-P) in patients (pts) with metastatic breast cancer (MBC): Results from a US health insurance database
Autor: Amy Ko, Deyanira Corzo, Debra A. Patt, Caihua Liang, Cheryl Enger, Ling Li, Cindy Duval Fraser
Publikováno v: Cancer Research. 75:P3-10
Background: nab-P, an albumin-bound formulation of paclitaxel, was approved in 2005 for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 mo of adjuvant chemotherapy based on clinical
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0c80a627f471cd57e66e4db6aa6bccd2
https://doi.org/10.1158/1538-7445.sabcs14-p3-10-06
Zobrazit plný text záznamu
4
nab-paclitaxel (nab-P) + nivolumab (Nivo) ± gemcitabine (Gem) in patients (pts) with advanced pancreatic cancer (PC)
Autor: Karen Kelly, Hatem Soliman, Victoria G. Manax, Howard S. Hochster, Irfan Firdaus, Ben George, Amy Ko, Daniel R. Carrizosa, Tanios Bekaii-Saab, Cindy Duval Fraser, Martin Gutierrez, Daniel W. Pierce, Zev A. Wainberg, Sotirios G. Stergiopoulos, David M. Waterhouse
Publikováno v: Journal of Clinical Oncology. 34:TPS475-TPS475
TPS475 Background: Nivo, an antibody against PD-1, is approved for unresectable or metastatic melanoma and metastatic squamous non-small cell lung cancer (NSCLC) after initial standard therapies. nab-P does not require immunosuppressive steroid preme
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b57cfc49f12ede0036b996c20381b3ad
https://doi.org/10.1200/jco.2016.34.4_suppl.tps475
Zobrazit plný text záznamu
5
Safety and efficacy of nab-paclitaxel (nab-P) in patients (pts) with metastatic breast cancer (MBC): Real-world results from a U.S. health insurance database
Autor: Debra A. Patt, Caihua Liang, Amy Ko, Cheryl Enger, Ling Li, Cindy Duval Fraser, Deyanira Corzo
Publikováno v: Journal of Clinical Oncology. 32:1075-1075
1075 Background: nab-P is an albumin-bound formulation of paclitaxel approved in 2005 for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy, based on an
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a01207b047b2f951f8e8c92d03e0385a
https://doi.org/10.1200/jco.2014.32.15_suppl.1075
Zobrazit plný text záznamu
6
The treatment patterns, efficacy, and safety of nab®-paclitaxel for the treatment of metastatic breast cancer in the United States: results from health insurance claims analysis
Autor: Ling Li, Amy Ko, Debra Patt, Cheryl Enger, Caihua Liang, Deyanira Corzo, Cindy Duval Fraser
Publikováno v: BMC Cancer
Background nab-Paclitaxel is an albumin-bound formulation of paclitaxel approved for the treatment of metastatic breast cancer (MBC). This analysis was designed to characterize the treatment patterns, efficacy, and safety of nab-paclitaxel for MBC tr
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0a12d2194080e98fd5f0c49c2609de58
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje